CDEK
← All drugs Report issue

pyrotinib

Small moleculeexperimental

Clinical trial activity

164 trials · 46 clinical orgs · 0 marketing orgs

Phase 1
28
Phase 2
134
Phase 3
21
Phase 4
3

Earliest trial started Jan 1, 2013 (NCT01937689)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C
Mol. weight
583.09 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pyrotinib
  • pyrotinib
  • pyrotinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07189884Phase 1/Phase 2 (Phase 2)Sep 23, 2025Xiamen University
NCT07179939Phase 2Sep 10, 2025Fudan University, Hengrui Therapeutics, Inc., People's Liberation Army of China
NCT06973525Phase 2Sep 1, 2025Hebei University
NCT07132242Phase 2Aug 30, 2025Cancer Hospital of Yunnan provinceal, Chinese Academy of Medical Sciences
NCT07180082Phase 2Aug 28, 2025Jiao Tong University
NCT07053150Phase 2Aug 15, 2025Hengrui Therapeutics, Inc., Huazhong University of Science and Technology, Innovent Biologics (Suzhou) Co. Ltd.
NCT07019337Phase 2Jun 30, 2025Chinese Academy of Medical Sciences
NCT06975475Phase 2Jun 1, 2025Huazhong University of Science and Technology
NCT06692491Phase 2Jan 1, 2025Peking University
NCT06718933Phase 1/Phase 2 (Phase 2)Dec 31, 2024Fudan University
NCT06718335N/ADec 30, 2024Cancer Hospital of Yunnan provinceal
NCT06563999Phase 2Dec 1, 2024Sun Yat-Sen University
NCT06770296Phase 1Nov 1, 2024Jiangsu University, Nanjing Medical University, Nantong University, Xuzhou Medical University
NCT06684600Phase 2Nov 1, 2024Peking University
NCT06495541N/AAug 1, 2024Tianjin Medical University
NCT06483386Phase 2Jul 15, 2024Tianjin Medical University
NCT06475443Phase 2Jun 15, 2024Henan Medical University
NCT06362096Phase 2May 31, 2024Huazhong University of Science and Technology
NCT06958627Phase 2/Phase 3 (Phase 3)Apr 30, 2024Chinese Academy of Medical Sciences
NCT05745740Phase 1/Phase 2 (Phase 2)Apr 30, 2024RemeGen
Showing 20 of 164 trials
Page 1 / 9

Organizations

Research & Development (46)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hengrui Therapeutics, Inc.For profit472232013
Chinese Academy of Medical SciencesAcademic/Hospital241952013
Fudan UniversityAcademic/Hospital232122018
Sun Yat-Sen UniversityAcademic/Hospital151322019
Jiao Tong UniversityAcademic/Hospital111022019
Nanjing Medical UniversityAcademic/Hospital9922021
Tianjin Medical UniversityAcademic/Hospital8822019
Henan Medical UniversityAcademic/Hospital7722018
Huazhong University of Science and TechnologyAcademic/Hospital6612015
Peking UniversityAcademic/Hospital6422020
Shengjing HospitalAcademic/Hospital6622020
Shandong UniversityAcademic/Hospital5532019
Fujian Medical UniversityAcademic/Hospital4422021
Hebei UniversityAcademic/Hospital4432019
Zhejiang UniversityAcademic/Hospital4412019
Central South UniversityAcademic/Hospital3212019
Wenzhou Medical UniversityAcademic/Hospital3222019
Xuzhou Medical UniversityAcademic/Hospital3022024
Anhui Medical UniversityAcademic/Hospital2012024
Cancer Hospital of Yunnan provincealAcademic/Hospital2122024
46 organizations
Page 1 / 3